B.11. MUTAGENICITY – *IN VIVO* MAMMALIAN BONE MARROW CHROMOSOME ABERRATION TEST

1. METHOD

This method is a replicate of the OECD TG 475, Mammalian Bone Marrow Chromosome Aberration Test (1997).

1.1 INTRODUCTION

The mammalian *in vivo* chromosome aberration test is used for the detection of structural chromosome aberrations induced by the test substance to the bone marrow cells of animals, usually rodents (1)(2)(3)(4). Structural chromosome aberrations may be of two types, chromosome or chromatid. An increase in polyploidy may indicate that a chemical has the potential to induce numerical aberrations. With the majority of chemical mutagens, induced aberrations are of the chromatid-type, but chromosome-type aberrations also occur. Chromosome mutations and related events are the cause of many human genetic diseases and there is substantial evidence that chromosome mutations and related events causing alterations in oncogenes and tumour suppressor genes are involved in cancer in humans and experimental systems.

Rodents are routinely used in this test. Bone marrow is the target tissue in this test, since it is a highly vascularised tissue, and it contains a population of rapidly cycling cells that can be readily isolated and processed. Other species and target tissues are not the subject of this method.

This chromosome aberration test is especially relevant to assessing mutagenic hazard in that it allows consideration of factors of *in vivo* metabolism, pharmacokinetics and DNA-repair processes although these may vary among species and among tissues. An *in vivo* test is also useful for further investigation of a mutagenic effect detected by *in vitro* test.

If there is evidence that the test substance, or a reactive metabolite, will not reach the target tissue, it is not appropriate to use this test.

See also General Introduction Part B.

1.2 DEFINITIONS

**Chromatid-type aberration**: structural chromosome damage expressed as breakage of single chromatids or breakage and reunion between chromatids.

**Chromosome-type aberration**: structural chromosome damage expressed as breakage, or breakage and reunion, of both chromatids at an identical site.

**Endoreduplication**: a process in which after an S period of DNA replication, the nucleus does not go into mitosis but starts another S period. The result is chromosomes with 4, 8, 16...chromatids.
Gap: an achromatic lesion smaller than the width of one chromatid, and with minimum misalignment of the chromatid(s).

Numerical aberration: a change in the number of chromosomes from the normal number characteristic of the cells utilised.

Polyploidy: a multiple of the haploid chromosome number (n) other than the diploid number (i.e. 3n, 4n and so on).

Structural aberration: a change in chromosome structure detectable by microscopic examination of the metaphase stage of cell division, observed as deletions and fragments, intrachanges or interchanges.

1.3 PRINCIPLE OF THE TEST METHOD

Animals are exposed to the test substance by an appropriate route of exposure and are sacrificed at appropriate times after treatment. Prior to sacrifice, animals are treated with a metaphase arresting agent (e.g. colchicine or Colcemid®). Chromosome preparations are then made from the bone marrow cells and stained, and metaphase cells are analysed for chromosome aberrations.

1.4 DESCRIPTION OF THE TEST METHOD

1.4.1 Preparations

1.4.1.1 Selection of animal species

Rats, mice and Chinese hamsters are commonly used, although any appropriate mammalian species may be used. Commonly used laboratory strains of young healthy adult animals should be employed. At the commencement of the study, the weight variation of animals should be minimal and not exceed ±20% of the mean weight of each sex.

1.4.1.2 Housing and feeding conditions

General conditions referred in the General Introduction to Part B are applied although the aim for humidity should be 50-60%.

1.4.1.3 Preparation of the animals

Healthy young adult animals are randomly assigned to the control and treatment groups. Cages should be arranged in such a way that possible effects due to cage placement are minimised. The animals are identified uniquely. The animals are acclimated to the laboratory conditions for at least five days.
1.4.1.4  **Preparation of doses**

Solid test substances should be dissolved or suspended in appropriate solvents or vehicles and diluted, if appropriate, prior to dosing of the animals. Liquid test substances may be dosed directly or diluted prior to dosing. Fresh preparations of the test substance should be employed unless stability data demonstrate the acceptability of storage.

1.4.2  **Test conditions**

1.4.2.1  **Solvent/Vehicle**

The solvent/vehicle should not produce toxic effects at the dose levels used, and should not be suspected of chemical reaction with the test substance. If other than well-known solvents/vehicles are used, their inclusion should be supported with data indicating their compatibility. It is recommended that wherever possible, the use of an aqueous solvent/vehicle should be considered first.

1.4.2.2  **Controls**

Concurrent positive and negative (solvent/vehicle) controls should be included for each sex in each test. Except for treatment with the test substance, animals in the control groups should be handled in an identical manner to the animals in the treated groups.

Positive controls should produce structural aberrations *in vivo* at exposure levels expected to give a detectable increase over background. Positive control doses should be chosen so that the effects are clear but do not immediately reveal the identity of the coded slides to the reader. It is acceptable that the positive control be administered by a route different from the test substance and sampled at only a single time. The use of chemical class related positive control chemicals may be considered, when available. Examples of positive control substances include:

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS No.</th>
<th>EINECS No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethyl methanesulphonate</td>
<td>62-50-0</td>
<td>200-536-7</td>
</tr>
<tr>
<td>Ethyl nitrosourea</td>
<td>759-73-9</td>
<td>212-072-2</td>
</tr>
<tr>
<td>Mitomycin C</td>
<td>50-07-7</td>
<td>200-008-6</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>50-18-0</td>
<td>200-015-4</td>
</tr>
<tr>
<td>Cyclophosphamide monohydrate</td>
<td>6055-19-2</td>
<td></td>
</tr>
<tr>
<td>Triethylenemelamine</td>
<td>51-18-3</td>
<td>200-083-5</td>
</tr>
</tbody>
</table>
Negative controls, treated with solvent or vehicle alone, and otherwise treated in the same way as the treatment groups, should be included for every sampling time, unless acceptable inter-animal variability and frequencies of cells with chromosome aberrations are available from historical control data. If single sampling is applied for negative controls, the most appropriate time is the first sampling time. In addition, untreated controls should also be used unless there are historical or published control data demonstrating that no deleterious or mutagenic effects are induced by the chosen solvent/vehicle.

1.5 PROCEDURE

1.5.1 Number and sex of animals

Each treated and control group must include at least 5 analysable animals per sex. If at the time of the study there are data available from studies in the same species and using the same route of exposure that demonstrate that there are no substantial differences in toxicity between sexes, then testing in a single sex will be sufficient. Where human exposure to chemicals may be sex-specific, as for example with some pharmaceutical agents, the test should be performed with animals of the appropriate sex.

1.5.2 Treatment schedule

Test substances are preferably administered as a single treatment. Test substances may also be administered as a split dose, i.e. two treatments on the same day separated by no more than a few hours, to facilitate administering a large volume of material. Other dose regimens should be scientifically justified.

Samples should be taken at two separate times following treatment on one day. For rodents, the first sampling interval is 1.5 normal cell cycle length (the latter being normally 12-18 hr) following treatment. Since the time required for uptake and metabolism of the test substance as well as its effect on cell cycle kinetics can affect the optimum time for chromosome aberration detection, a later sample collection 24 hr after the first sample time is recommended. If dose regimens of more than one day are used, one sampling time at 1.5 normal cell cycle lengths after the final treatment should be used.

Prior to sacrifice, animals are injected intraperitoneally with an appropriate dose of a metaphase arresting agent (e.g. Colcemid® or colchicine). Animals are sampled at an appropriate interval thereafter. For mice this interval is approximately 4-5 hours. Cells are harvested from the bone marrow and analysed for chromosome aberrations.
1.5.3 Dose levels

If a range finding study is performed because there are no suitable data available, it should be performed in the same laboratory, using the same species, strain, sex, and treatment regimen to be used in the main study (5). If there is toxicity, three dose levels are used for the first sampling time. These dose levels should cover a range from the maximum to little or no toxicity. At the later sampling time only the highest dose needs to be used. The highest dose is defined as the dose producing signs of toxicity such that higher dose levels, based on the same dosing regimen, would be expected to produce lethality. Substances with specific biological activities at low non-toxic doses (such as hormones and mitogens) may be exceptions to the dose-setting criteria and should be evaluated on a case-by-case basis. The highest dose may also be defined as a dose that produces some indication of toxicity in the bone marrow (e.g. greater than 50% reduction in mitotic index).

1.5.4 Limit test

If a test at one dose level of at least 2000 mg/kg body weight using a single treatment, or as two treatments on the same day, produces no observable toxic effects, and if genotoxicity would not be expected based on data from structurally related substances, then a full study using three dose levels may not be considered necessary. For studies of a longer duration, the limit dose is 2000 mg/kg body weight/day for treatment up to 14 days, and 1000 mg/kg body weight/day for treatment longer than 14 days. Expected human exposure may indicate the need for a higher dose level to be used in the limit test.

1.5.5 Administration of doses

The test substance is usually administered by gavage using a stomach tube or a suitable intubation cannula, or by intraperitoneal injection. Other routes of exposure may be acceptable where they can be justified. The maximum volume of liquid that can be administered by gavage or injection at one time depends on the size of the test animal. The volume should not exceed 2 ml/100g body weight. The use of volumes higher than these must be justified. Except for irritating or corrosive substances which will normally reveal exacerbated effects with higher concentrations, variability in test volume should be minimised by adjusting the concentration to ensure a constant volume at all dose levels.

1.5.6 Chromosome preparation

Immediately after sacrifice, bone marrow is obtained, exposed to hypotonic solution and fixed. The cells are then spread on slides and stained.
1.5.7 Analysis

The mitotic index should be determined as a measure of cytotoxicity in at least 1000 cells per animal for all treated animals (including positive controls) and untreated negative control animals.

At least 100 cells should be analysed for each animal. This number could be reduced when high numbers of aberrations are observed. All slides, including those of positive and negative controls, should be independently coded before microscopic analysis. Since slide preparation procedures often result in the breakage of a proportion of metaphases with loss of chromosomes, the cells scored should therefore contain a number of centromeres equal to the number $2n \pm 2$.

2. DATA

2.1 TREATMENT OF RESULTS

Individual animal data should be presented in tabular form. The experimental unit is the animal. For each animal the number of cells scored, the number of aberrations per cell and the percentage of cells with structural chromosome aberration(s) should be evaluated. Different types of structural chromosome aberrations should be listed with their numbers and frequencies for treated and control groups. Gaps are recorded separately and reported but generally not included in the total aberration frequency. If there is no evidence for a difference in response between the sexes, the data from both sexes may be combined for statistical analysis.

2.2 EVALUATION AND INTERPRETATION OF RESULTS

There are several criteria for determining a positive result, such as a dose-related increase in the relative number of cells with chromosome aberrations or a clear increase in the number of cells with aberrations in a single dose group at a single sampling time. Biological relevance of the results should be considered first. Statistical methods may be used as an aid in evaluating the test results (6). Statistical significance should not be the only determining factor for a positive response. Equivocal results should be clarified by further testing preferably using a modification of experimental conditions.

An increase in polyploidy may indicate that the test substance has the potential to induce numerical chromosome aberrations. An increase in endoreduplication may indicate that the test substance has the potential to inhibit cell cycle progression (7)(8).

A test substance for which the results do not meet the above criteria is considered non-mutagenic in this test.

Although most experiments will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of experiments performed.

Positive results from the in vivo chromosome aberration test indicate that a substance induces chromosome aberrations in the bone marrow of the species tested. Negative results indicate that, under the test conditions, the test substance does not induce chromosome aberrations in the bone marrow of the species tested.

The likelihood that the test substance or its metabolites reach the general circulation or specifically the target tissue (e.g. systemic toxicity) should be discussed.
3. REPORTING

TEST REPORT

The test report must include the following information:

Solvent/Vehicle
— justification for choice of vehicle;
— solubility and stability of the test substance in solvent/vehicle, if known;

Test animals:
— species/strain used;
— number, age and sex of animals;
— source, housing conditions, diet, etc.;
— individual weight of the animals at the start of the test, including body weight range, mean and standard deviation for each group;

Test conditions:
— positive and negative (vehicle/solvent) controls;
— data from range-finding study, if conducted;
— rationale for dose level selection;
— details of test substance preparation;
— details of the administration of the test substance;
— rationale for route of administration;
— methods for verifying that the test substance reached the general circulation or target tissue, if applicable;
— conversion from diet/drinking water test substance concentration (ppm) to the actual dose (mg/kg body weight/day), if applicable;
— details of food and water quality;
— detailed description of treatment and sampling schedules;
— methods for measurements of toxicity;
— identity of metaphase arresting substance, its concentration and duration of treatment;
— methods of slide preparation;
— criteria for scoring aberrations;
— number of cells analysed per animal;
— criteria for considering studies as positive, negative or equivocal.
Results:

— signs of toxicity;
— mitotic index;
— type and number of aberrations, given separately for each animal;
— total number of aberrations per group with means and standard deviations;
— number of cells with aberrations per group with means and standard deviations;
— changes in ploidy, if seen;
— dose-response relationship, where possible;
— statistical analyses, if any;
— concurrent negative control data;
— historical negative control data with ranges, means and standard deviations;
— concurrent positive control data.

Discussion of the results.

Conclusions.

REFERENCES


